Ordering Prevnar 13^® for Your Patients

You can easily order Prevnar 13^® directly through Pfizer's online ordering system. Online ordering allows you to submit an order that will ship in 1-2 business days.

New Customers

To establish a new online ordering account, please contact a customer service representative at
1-800-666-7248.

Existing Customers

Already have an online ordering account? You can manage your account or place a new order by
clicking here.

INDICATIONS

Prevnar 13^® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
In adults 50 years and older for pneumococcal pneumonia and invasive disease. Indication is
based on immune responses
In children 6 weeks through 5 years for invasive pneumococcal disease and otitis media (caused
by 7 of the 13 serotypes only [4, 6B, 9V, 14, 18C, 19F, and 23F])

Limitations of Use and Effectiveness

Prevnar 13^® will only help protect against S pneumoniae serotypes in the vaccine
Effectiveness when administered <5 years after pneumococcal polysaccharide vaccine is not known

IMPORTANT SAFETY INFORMATION

Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13^® or any diphtheria
toxoid–containing vaccine is a contraindication
Immunocompromised individuals or individuals with impaired immune responsiveness due to the
use of immunosuppressive therapy may have reduced antibody response
In adults, antibody responses to Prevnar 13^® were diminished when given with inactivated
Influenza Virus Vaccine
In adults, the commonly reported solicited adverse reactions were pain, redness, and swelling at
the injection site, limitation of arm movement, fatigue, headache, muscle or joint pain, decreased
appetite, chills, or rash
Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status, and the potential benefits and risks
In infants and toddlers, the most commonly reported serious adverse events were
bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
In infants and toddlers, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep,
and fever

Please see full Prescribing Information for Prevnar 13^®

These documents are in PDF (portable document format).
PDF files require Adobe Reader click here to download this free program.

PREVNAR 13 is a registered trademark of Wyeth LLC.